NAPA, Calif., Sept. 11 /PRNewswire/ -- Dey, L.P. unequivocally denies any wrongdoing in the pricing or marketing of its generic or branded pharmaceutical products. In response to claims filed by the Department of Justice (DOJ), DEY maintains that it has consistently participated legally and ethically within national and state reimbursement systems. DEY intends to defend itself vigorously against the DOJ’s claims.
